Company Interview / Recce on track to tackle Indonesia's obesity crisis

James Graham, CEO of Recce Pharmaceuticals (ASX:RCE) shares that the company is advancing its antibiotic treatments for diabetic foot infections. Recce (ASX:RCE) has received approval for a phase three clinical trial in Indonesia, targeting a population of 280 million, 11% of which have diabetes. James sees this as a gateway to the ASEAN markets, reaching 700 million people, presenting significant commercial opportunities.

James states that the trials have shown promising results, with 100% of phase two participants responding positively. The Indonesian and Australian governments support Recce's efforts, recognising the antibiotic as the first new class in over 40 years. Financial benefits include a 43.5% R&D rebate on a $2 million study cost, aiding production and market access.

Recce (ASX:RCE) aims for broad-spectrum applications, moving towards phase three studies focused on the US, FDA, and Europe. James envisions two product tiers: a premium one aligning with FDA standards and a cost-effective option for broader markets, including the Middle East, India, and potentially the UK post-Brexit. Commercialisation is expected within 18 months.